Calyx Supply Simulation Service Launched
Service uses simulation modeling methodology to evaluate the quantity of medication produced for use in clinical development.
E-Clinical and Regulatory solutions and services provider Calyx has announced its Calyx Supply Simulation clinical trial supply forecasting service. Available through the company’s in-house statistical design and trial supplies consultants, the service uses simulation modeling methodology and over 50 design parameters that closely mimic an Interactive Response Technology (IRT) system, to evaluate the quantity of medication produced for use in clinical development.
By providing better-aligned medication scenarios—for trial start-up and continued enrollment, how long an existing amount of study medication will last and determining optimal site and depot buffer stock quantities—can help sponsors reduce cost and excessive drug wastage.
Reference: Calyx Launches Supply Simulation Service to Forecast and Optimize Clinical Trial Supplies; Nottingham, England and Morrisville, NC. March 7, 2023
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
